{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:11:53Z","timestamp":1773029513398,"version":"3.50.1"},"reference-count":106,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The aberrant overexpression of Enhancer of Zeste Homolog 2 (EZH2) endorses uncontrolled cell proliferation and metastasis across multiple malignancies. These make EZH2 an attractive biological target for the development of potential anticancer molecules. Following the approval of Tazemetostat, the last 5 years have witnessed extensive medicinal chemistry efforts to refine EZH2 inhibitors to explore dual\u2010target hybrids. This review comprehensively surveys the chemical diversity, synthetic approaches, pharmacological activity, and SAR analysis of emerging pyridone\u2010 and non\u2010pyridone\u2010based scaffolds that modulate EZH2, either selectively or in combination with other targets, such as PARP, BRD4, HDAC6, or HSP90. A comparative analysis of enzymatic and cytotoxic activities was conducted. Results revealed strong translational correlation for lead compounds, such as\n                    <jats:bold>N40<\/jats:bold>\n                    and\n                    <jats:bold>136<\/jats:bold>\n                    , which exhibit sub\u2010nanomolar inhibition and potent cytotoxicity in lymphoma models. Conversely, multitarget hybrids such as Olaparib\u2010Tazemetostat (\n                    <jats:bold>33<\/jats:bold>\n                    ) and Tazemetostat\u2010resorcinol (\n                    <jats:bold>170<\/jats:bold>\n                    ) maintained robust cellular efficacy through synergistic epigenetic and DNA\u2010repair modulation. The reviewed EZH2 inhibitors illustrate significant progress in improving selectivity and mutation resilience, while highlighting persisting challenges with off\u2010target epigenetic effects and resistance mechanisms. Future perspectives emphasize rational design strategies integrating dual targeting, computational modeling, and covalent functionalities to enhance therapeutic durability. Collectively, these advances explain the evolving therapeutic horizon of non\u2010PROTAC and dual EZH2 inhibitors, offering an outline for next\u2010generation EZH2 inhibitors.\n                  <\/jats:p>","DOI":"10.1002\/ardp.70212","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:15:49Z","timestamp":1772964949000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Horizons in Targeting EZH2 With Dual and Non\u2010PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives"],"prefix":"10.1002","volume":"359","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6479-4573","authenticated-orcid":false,"given":"Hamada S.","family":"Abulkhair","sequence":"first","affiliation":[{"name":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Al\u2010Azhar University  Nasr City Cairo Egypt"},{"name":"Pharmaceutical Chemistry Department, Faculty of Pharmacy Horus University\u2010Egypt  New Damietta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2025.2482555"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00047"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216706"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0122-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083737"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11272-w"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.05.018"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112617"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01876"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109530"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02261"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117386"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02234"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500203"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03119-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116154"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92526"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000166"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814634116"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.571"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.08.018"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1116418109"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2012.07.066"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-321208"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad085"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14576"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03472-z"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29245817"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241306026"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17501911.2024.2410693"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188700"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899599"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00653-6"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02208-x"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-022-00850-x"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI195840"},{"key":"e_1_2_11_40_1","unstructured":"\u201cFDA Approves Tazemetostat for Advanced Epithelioid Sarcoma \u201d FDA accessed November 3 2025 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tazemetostat-advanced-epithelioid-sarcoma."},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.2.7"},{"key":"e_1_2_11_42_1","unstructured":"\u201cFDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma \u201d FDA accessed November 3 2025 https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-024-04658-4"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1244"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1084"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-023-03105-y"},{"key":"e_1_2_11_48_1","unstructured":"EZH2 Selective Inhibitors accessed October 12 2025 https:\/\/www.selleckchem.com\/subunits\/EZH2_EZH1\/2_selpan.html."},{"key":"e_1_2_11_49_1","unstructured":"\u201cIn Advanced or Metastatic Solid Tumors \u201d Dose Escalation and Expansion Study of HM97662 accessed October 9 2025 https:\/\/clinicaltrials.gov\/study\/NCT05598151."},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00437"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01154"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10142-025-01563-8"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-804344"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01285-3"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1141"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0110"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101313"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-024-00716-z"},{"key":"e_1_2_11_59_1","unstructured":"\u201cA Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors \u201d accessed 5 October 2025 https:\/\/clinicaltrials.gov\/study\/NCT06244485?limit=10&sort=@relevance."},{"key":"e_1_2_11_60_1","unstructured":"\u201cEZH2 Inhibition for Prostate Cancer; It's Taken Awhile but We Just May Be onto Something Here \u201d UroToday accessed October 12 2025 https:\/\/www.urotoday.com\/clinical-trials\/from-the-editor\/158604-ezh2-inhibition-for-prostate-cancer-it-s-taken-awhile-but-we-just-may-be-onto-something-here.html."},{"key":"e_1_2_11_61_1","unstructured":"\u201cThe PREDICT Trial (PREDICT) \u201d NCI Targeted Treatment for Metastatic Prostate Cancer accessed October 12 2025 https:\/\/clinicaltrials.gov\/study\/NCT06632977."},{"key":"e_1_2_11_62_1","unstructured":"\u201cCastration Resistant Prostate Cancer and Follicular Lymphoma \u201d Mevrometostat Treatment of Relapsed\/Refractory SCLC accessed November 9 2025 https:\/\/clinicaltrials.gov\/study\/NCT03460977."},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180444"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad141"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18871"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252658"},{"key":"e_1_2_11_67_1","unstructured":"\u201cTazemetostat (EPZ\u20106438) is a Potent %2C and selective and %3E4%2C500\u2010fold Selectivity Relative to 14 Other HMTs \u201d Selleckchem accessed November 3 2025 https:\/\/www.selleckchem.com\/products\/epz-6438.html#:~:text=Tazemetostat.%28EPZ-6438%2C.E7438%29."},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-020-01677-7"},{"key":"e_1_2_11_69_1","first-page":"199","volume-title":"Chemistry and Pharmacology of Drug Discovery","author":"Jack Li J.","year":"2024"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2026.2636498"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-025-00845-4"},{"key":"e_1_2_11_72_1","unstructured":"\u201cASCO GU 2025: Mevrometostat (PF\u201006821497) an EZH2 Inhibitor in Combination With Enzalutamide in Patients With mCRPC: A Randomized Dose\u2010Expansion Study \u201d American Society of Clinical Oncology accessed October 12 2025 https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2025\/asco-gu-2025-prostate-cancer\/158201-asco-gu-2025-mevrometostat-pf-06821497-an-ezh2-inhibitor-in-combination-with-enzalutamide-in-patients-with-mcrpc-a-randomized-dose-expansion-study.html."},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00567"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.108070"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1039\/D5RA08746E"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400802"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202500033"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118389"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2025.2587561"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.109305"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.21608\/ejchem.2025.357091.11242"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1039\/d2nj02061k"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1039\/D5RA07972A"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00673"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129726"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129558"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0421-4"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02053"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114462"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11384"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"e_1_2_11_92_1","unstructured":"D. S.Biovia Discovery Studio Modeling Environment 2017 https:\/\/www.materials-studio.com\/products\/collaborative-science\/biovia-discovery-studio\/."},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2017.04.014"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115661"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000170"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01607"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117725"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.714"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.810101"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117773"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106397"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2167000"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00003"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02112"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01240-3"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01370"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0646"}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.70212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ardp.70212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.70212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:30:11Z","timestamp":1773027011000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.70212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/ardp.70212"],"URL":"https:\/\/doi.org\/10.1002\/ardp.70212","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"value":"0365-6233","type":"print"},{"value":"1521-4184","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70212"}}